Introduction
============

Gastric cancer (GC) ranks fifth for cancer incidence and third for cancer deaths worldwide,[@b1-tcrm-14-965] and surgery is the most important therapeutic strategy in patients with resectable GC. China is classified as a high-incidence area for GC, with the third highest incidence and the second leading cause of death among all cancers.[@b2-tcrm-14-965] Despite the improvements of preoperative management and surgical technique, postoperative complications are still a common problem. Due to the intricacy of operative procedures, the incidence of complications after radical gastrectomy can be as high as 20%.[@b3-tcrm-14-965] Reportedly, 2%--10% patients with these complications need reoperation.[@b4-tcrm-14-965],[@b5-tcrm-14-965] Unplanned reoperation (URO) may result in psychological and physical problems, increase financial burden, prolong hospital stay, and even lead to death.[@b6-tcrm-14-965]--[@b9-tcrm-14-965] Therefore, decreasing the incidence of postoperative complications and reoperation rate is of great importance in clinical practice.

Several studies reported the risk factors for GC postoperative complications.[@b3-tcrm-14-965],[@b10-tcrm-14-965]--[@b13-tcrm-14-965] Deguchi et al showed that pulmonary insufficiency and the duration of the operation are independent risk factors for anastomotic leakage.[@b10-tcrm-14-965] According to Kobayashi et al's study, dissection of the pancreas head area is an unfavorable predictor for postoperative pancreatic fistula after laparoscopic gastrectomy.[@b13-tcrm-14-965] However, substantial heterogeneity existed in previous studies and their findings were inconsistent. Furthermore, our knowledge of the impact of URO on long-term survival after radical gastrectomy is still limited. Thus, investigation into the relationship between URO and tumor prognosis is duly warranted.

The aim of this study is to systematically evaluate the risk factors for URO after radical gastrectomy and to explore the potential correlation between URO and long-term survival outcomes for patients. Our results may increase the awareness of URO among surgeons and prevent the occurrence of these undesirable postoperative events after surgery.

Patients and methods
====================

Patient population
------------------

This study was designed as a retrospective analysis of GC patients treated with gastrectomy in the Department of Gastrointestinal Surgery, the First Affiliated Hospital of Wannan Medical College. A total of 2,992 patients undergoing gastrectomy for GC between January 2011 and December 2014 were enrolled. Exclusion criteria were as follows: 1) patients diagnosed with non-adenocarcinoma: squamous cell carcinoma (n = 14), adenosquamous carcinoma (n = 4), and neuroendocrine carcinoma (n = 21); 2) patients who did not receive D2 radical resection: open-close surgery (n = 27), non-R0 resection (n = 35), and postoperative American Joint Committee on Cancer (AJCC) stage IV (n = 17); and 3) patients undergoing emergency surgery (n = 22). Together, 2,852 patients were ultimately included for further analyses. Among them, 39 patients were termed as the URO group and 2,813 as the non-URO group ([Figure 1](#f1-tcrm-14-965){ref-type="fig"}). This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. The current research was reviewed and approved by the ethical review board of the First Affiliated Hospital of Wannan Medical College. Written informed consent was obtained from all patients.

Data collection and definitions
-------------------------------

Patient information, medical history, concomitant diseases, primary surgical treatment, postoperative complications, clinical outcomes, and follow-up data were retrieved from the electronic database of the First Affiliated Hospital of Wannan Medical College. The postoperative pathological stages were determined according to the AJCC 8th Edition of Gastric Cancer TNM Staging.[@b14-tcrm-14-965]

In this study, URO was defined as the status that the patient had to receive reoperation under general anesthesia and tracheal intubation due to severe postoperative complications caused by the initial gastrectomy for GC. Neo-adjuvant chemotherapy was administered to patients with a preoperative staging cT3/4 or cN^+^, based on the decision after multidisciplinary discussion.[@b15-tcrm-14-965] Adjuvant combination chemotherapy was routinely implemented to all patients with postoperative staging II and III with oxaliplatin plus 5-FU/leucovorin (FOLFOX) or capecitabine (CapeOX) for 4--6 cycles. Cancer-specific survival refers to the time from the first gastrectomy to death of recurrence and metastasis.

Operative techniques
--------------------

All operations were performed by experienced surgeons specializing in gastrointestinal surgery at our center. The surgeons had performed at least 100 D2 radical gastrectomies. Anticoagulants were discontinued 1 week before surgery. Depending on the location of the foci, total or partial gastrectomy was performed with D2 lymph node dissection, according to the new Japanese classifications and treatment guidelines for GC.[@b16-tcrm-14-965] The following methods were adopted for reconstruction after gastrectomy: Roux-en-Y reconstruction following total gastrectomy, Billroth-I or Billroth-II reconstruction following distal gastrectomy, and esophagogastrostomy following proximal gastrectomy.

Follow-up
---------

As shown in [Figure 1](#f1-tcrm-14-965){ref-type="fig"}, five patients who died within 30 days after URO were excluded from survival analysis. We followed-up all patients surviving the procedure of URO (n = 34) and 136 patients in the non-URO group who were randomly selected by propensity score matching based on the clinicopathological features, including postoperative AJCC stage, age, gender, body mass index, concomitant diseases, diabetes, preoperative hypoproteinemia, and preoperative anemia, with a ratio of 1:4. Follow-up data were obtained by telephone or email and the outpatient/inpatient clinical records. The last follow-up time was December 2017.

Statistical analysis
--------------------

The risk factors included in the univariate analysis were age, gender, concomitant diseases, diabetes, preoperative hypoproteinemia, preoperative anemia, tumor size, type of surgical resection, type of reconstruction, surgical approach, combined organ resection, neoadjuvant chemotherapy, and postoperative AJCC stage. Categorical data were shown as percentages and were analyzed with Fisher's exact test. Continuous data were presented as mean ± standard errors of the mean, and differences between groups were analyzed by the Mann--Whitney *U* test. All clinical variables were included in a multivariate logistic regression model. Moreover, propensity score analysis was performed as a superior and more refined statistical method of adjusting for potential baseline confounding variables.[@b17-tcrm-14-965] The baseline risk profiles of the matched patients were compared to assure that no major differences in baseline patient characteristics persisted. The prognostic value of URO for cancer-specific survival was finally assessed using the Kaplan--Meier method and multivariate Cox proportional hazard model analysis after the propensity score matching. R statistical software was used to conduct propensity score matching, and all analyses were performed using the SPSS 24.0 software (IBM Corporation, Armonk, NY, USA). A two-sided *P*-value \< 0.05 was considered statistically significant.

Results
=======

Severe complications, primary causes, and management of URO
-----------------------------------------------------------

We included 2,104 males and 748 females in this study. The mean age was 65.0 ± 9.3 years. Among the enrolled 2,852 patients, 39 cases (mean age: 62.1 ± 10.1 years) underwent URO, including 36 males and three females. The primary causes of URO were intra-abdominal bleeding (15/39, 38.5%), anastomotic leakage and intra-abdominal bleeding (6/39, 15.4%), incision dehiscence (6/39, 15.4%), intestinal obstruction (4/39, 10.2%), anastomotic leakage and intra-abdominal infection (3/39, 7.7%), jejunal perforation (3/39, 7.7%), and anastomotic bleeding (2/39, 5.1%).

The total incidence of URO resulting from intra-abdominal bleeding was 53.9% (21/39), and all bleeding cases were confirmed by arterial angiography or open surgery. Splenic area was the most common site of bleeding found during the reoperation (5/21, 23.8%). The primary causes of bleeding were associated with operative technique failure (13/21, 61.9%) and anastomotic leakage (6/21, 28.6%). Regarding the treatment of bleeding caused by anastomotic leakage, suturing the bleeding vessels and adequate abdominal drainage were necessary. Among the 21 patients with postoperative bleeding, 18 patients recovered after URO, while three patients died. Eight patients required a third operation due to re-bleeding. The detailed causes, treatments, and outcomes of URO patients with intra-abdominal bleeding are presented in [Table 1](#t1-tcrm-14-965){ref-type="table"}.

Risk factors for URO
--------------------

As shown in [Table 2](#t2-tcrm-14-965){ref-type="table"}, three factors including male gender (*P* = 0.005), diabetes (*P* = 0.010), and preoperative hypoproteinemia (*P* = 0.035) were closely correlated with URO. Furthermore, the multivariate analysis using logistic regression demonstrated that male gender (OR = 4.630, 95% CI = 1.412--15.152, *P* = 0.011), diabetes (OR = 4.189, 95% CI = 1.705--10.290, *P* = 0.002), and preoperative hypoproteinemia (OR = 2.305, 95% CI = 1.079--4.923, *P* = 0.031) were independent risk factors for URO ([Table 3](#t3-tcrm-14-965){ref-type="table"}).

Early surgical outcomes of the URO patients
-------------------------------------------

After reoperation, 19 patients developed postoperative complications, including re-bleeding, pulmonary infection, ileus, and incision infection. The incidence of postoperative complications after URO was 48.7% (19/39), whereas the incidence was 14.0% (396/2,813) in the non-URO group. Furthermore, patients with URO had a significantly increased time of hospital stay (35.03 ± 14.85 vs 15.52 ± 6.16 days, *P* \< 0.001). Compared with the non-URO group (six out of the 2,813 patients), five out of 39 patients with URO died of disseminated intravascular coagulation (DIC) or multiple organ dysfunction syndrome during hospitalization. The mortality was 12.8% (5/39) in the URO group and 0.2% (6/2,813) in the non-URO group (*P* \< 0.001). Together, URO was correlated with prolonged hospital stay, increased in-hospital complications, and higher perioperative mortality ([Table 4](#t4-tcrm-14-965){ref-type="table"}).

Assessment of URO as a prognostic factor for long-term survival
---------------------------------------------------------------

A total of 34 URO patients and 136 propensity matched patients without URO were included in the long-term follow-up analysis. The propensity score in patients who underwent URO was 0.028 ± 0.005, compared with 0.030 ± 0.004 in those who did not undergo URO (*P* = 0.782), indicating no significant bias in the patient characteristics. The median follow-up time was 56 months. The 1- and 3-year cancer-specific survival rates of patients with URO were 88.23% (30/34) and 47.1% (16/34), and 97.8% (133/136) and 56.6% (77/136) in patients without URO. According to the univariate and multivariate survival analyses, URO was not associated with cancer-specific survival (*P* = 0.275) ([Figure 2](#f2-tcrm-14-965){ref-type="fig"} and [Table 5](#t5-tcrm-14-965){ref-type="table"}). In addition, AJCC stage (HR = 7.004, 95% CI = 2.130--23.034, *P* = 0.001) and preoperative hypoproteinemia (HR = 1.831, 95% CI = 1.126--2.978, *P* = 0.015) significantly affected the cancer-specific survival in this study. Taken together, URO might not be correlated with long-term cancer-specific survival of GC patients.

Discussion
==========

Reoperation following surgery is correlated with higher morbidity, mortality, and cost to the health care system.[@b18-tcrm-14-965] The URO rate, recognized as a compelling evaluation index of surgical quality, has drawn increasing attention from surgeons.[@b19-tcrm-14-965] URO is typically associated with a more complicated postoperative course, particularly for complex surgical procedures such as gastric resection. Knowledge regarding the risk factors and indications for URO could provide valuable insight. In this study, we elucidated the causes, risk factors, early outcomes, and long-term cancer-specific survival of URO after radical gastrectomy for GC. Notably, URO was found not to be correlated with the long-term cancer-specific survival according to our data.

In recent years, the incidence of URO has declined over the past years with the rapid development of surgical techniques. According to Sah et al's study, URO incidence after open gastrectomy for GC is 2.2%, and the primary causes of URO are intra-abdominal bleeding and anastomotic leakage.[@b20-tcrm-14-965] Li et al reported that the morbidity of patients undergoing URO after laparoscopic gastrectomy is 1.1%, and the main reasons for URO are intra-abdominal hemorrhage and anastomotic bleeding.[@b21-tcrm-14-965] This study enrolled a much larger population and suggested that the URO incidence was 1.4%, with intra-abdominal bleeding and anastomotic leakage being the major causes. In addition, our data showed that intra-abdominal bleeding was the most common complication after gastrectomy.

Previous studies indicated that early postoperative bleeding is associated with surgeons' technical failure,[@b12-tcrm-14-965],[@b22-tcrm-14-965] such as lack of experience in the procedure of hemostasis and vessel ligatures, and anastomotic bleeding. Abdominal arterial bleeding usually occurs in splenic artery, hepatic artery, and gastroduodenal artery, with the incidence ranging from 0.6% to 3.3%, and the main reason for hemorrhage was anastomotic leakage.[@b23-tcrm-14-965],[@b24-tcrm-14-965] Esophagojejunal anastomotic leakage after total gastrectomy and Roux-en-Y reconstruction was the primary reason for delayed massive abdominal bleeding. Severe postoperative hemorrhage was an extremely intractable complication which lacks standardized treatment, leading to high postoperative mortality.[@b4-tcrm-14-965],[@b8-tcrm-14-965] In this study, three out of eight re-bleeding patients died of DIC, while the remaining patients eventually recovered after one or more transcatheter arterial embolizations (TAEs) and/or surgical operations. Early postoperative arterial bleeding can be managed effectively by immediate re-laparotomy, with a satisfactory clinical outcome.[@b25-tcrm-14-965] However, re-laparotomy is often difficult to perform in the latter phase as the bleeding site is hard to find due to intraperitoneal adhesion and inflammatory reaction. Alternatively, TAE is a less invasive approach, irrespective of tissue adhesion and edema caused by the initial surgery. Nevertheless, TAE had a higher re-bleeding rate compared to re-laparotomy.[@b26-tcrm-14-965],[@b27-tcrm-14-965] In case radiological intervention fails, immediate shift to surgical treatment is compulsory.[@b28-tcrm-14-965],[@b29-tcrm-14-965]

As URO can cause great harm to patients, it is crucial for surgeons to evaluate the risk factors for URO before surgery, which might assist surgeons in preventing URO. Several risk factors for URO after radical gastrectomy proposed by previous studies were not completely coincident. According to Yi et al's report,[@b5-tcrm-14-965] tumor size and type of operation are risk factors for URO. One study performed by Oh et al suggested that male gender and increased mean age are closely correlated with the incidence of URO.[@b4-tcrm-14-965] Consistently, Li et al indicated that there are more elderly, male, and overweight patients in the URO group.[@b21-tcrm-14-965] In this study, we found that male gender, diabetes, and preoperative hypoproteinemia were independent risk factors for URO.

Additionally, we suggested that URO might have no impact on the long-term cancer-specific survival of the patients after radical gastrectomy, though URO impaired the early surgical outcomes. Several studies concluded that intraoperative blood loss, TNM stage, operation duration, and neoadjuvant chemotherapy are prognostic factors for patient survival.[@b30-tcrm-14-965] Nakauchi et al found that tumor size, pathological N factor ≥2, and postoperative pancreatic fistula combined with intra-abdominal abscesses are associated with the 3-year recurrence free survival.[@b31-tcrm-14-965] This study suggested that there was no significant relationship between URO and long-term cancer-specific survival. Given that the occurrence of URO is multifactorial, we conducted a matched follow-up study to minimize the potential effect of these confounding variables. The patients from the URO group and the non-URO group were 1:4 propensity score matched according to multiple clinicopathological characteristics. Multivariate Cox analysis revealed that TNM stage III and preoperative hypoproteinemia were significant unfavorable prognostic factors for cancer-specific survival, further confirming the robustness and reliability of our results.

In spite of our efforts to conduct a comprehensive and accurate analysis, there were still several limitations in this study. First, the clinical characteristics of the Asian population may result in potential selection bias which limits its universal value. Our findings should be considered valid in the geographical-ethnical-social context and need to be verified in different populations with different phenotypes. Second, this was a retrospective study performed in a single center. Large multicenter prospective studies are duly warranted to further verify our results. Third, despite the large total sample size in this study, the sample size of URO patients was relatively small because of the low incidence of URO. Fourth, due to disparities among the treatment strategies of patients and intricate complications, potential bias might affect our results. Therefore, multi-institutional prospective cohort studies are needed for further confirmation. However, this study included a larger population than previous pertinent research, and the follow-up data were analyzed to evaluate the long-term survival of URO patients for the first time.

Conclusion
==========

This study suggests that male gender, diabetes, and preoperative hypoproteinemia might be risk factors for URO after gastrectomy for GC. URO was associated with increased time of hospital stay and higher perioperative mortality but might not be correlated with long-term survival. These findings may assist in the identification of patients at high risk for URO that may benefit from preoperative counseling, optimization, and tailoring of postoperative management to reduce the rate of reoperation.
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###### 

Intra-abdominal bleeding position, cause, and treatment

  Position                       Cases (%)    Mean interval days   Cause                                      Treatment                                   Outcome
  ------------------------------ ------------ -------------------- ------------------------------------------ ------------------------------------------- -------------------------------------------------
  Splenic artery                 4 (19.0)     22.5                 Technical failure or anastomotic leakage   Suture, TAE Suture and abdominal drainage   Two patients died of re-bleeding, two recovered
  Superior pancreatic vessels    3 (14.2)     0.2                  Technical failure                          Suture                                      One patient re-bled, two recovered
  Right gastroepiploic vessels   2 (9.5)      9.8                  Technical failure or anastomotic leakage   Suture Suture and abdominal drainage        One patient re-bled, the other recovered
  Gastroduodenal artery          2 (9.5)      9.5                  Anastomotic leakage                        Suture and abdominal drainage               One patient died of re-bleeding, one recovered
  Transverse mesocolon vessels   1 (4.8)      0.8                  Technical failure                          Suture                                      Recovered
  Right gastric artery           1 (4.8)      19                   Abdominal infection                        Suture and abdominal drainage               Re-bled
  Spleen                         1 (4.8)      4                    Technical failure                          Splenectomy                                 Recovered
  Abdominal wall muscle          1 (4.8)      8                    Technical failure                          Suture                                      Recovered
  Gastric wall                   1 (4.8)      20                   Gastric necrosis                           Gastrectomy                                 Recovered
  Unidentified                   5 (23.8)     4.5                  Technical failure                          Suture                                      Two patients re-bled, three recovered
  Total                          21 (100.0)   9.7                  --                                         --                                          --

**Note:** Mean interval days: the time between the first operation and the unplanned reoperation.

**Abbreviation:** TAE, transcatheter arterial embolization.

###### 

Univariate analysis of potential influencing factors for URO

  Variables                      Non-URO group (n, %)   URO group (n, %)   *P*-value
  ------------------------------ ---------------------- ------------------ ---------------------------------------------------
  Gender                                                                   0.005[\*](#tfn3-tcrm-14-965){ref-type="table-fn"}
   Male                          2,068 (73.5)           36 (92.3)          
   Female                        745 (26.5)             3 (7.7)            
  Age (years)                                                              0.088
   \<60                          972 (34.6)             8 (20.5)           
   ≥60                           1,841 (65.4)           31 (79.5)          
  BMI (kg/m^2^)                                                            0.094
   ≤25                           2,315 (82.3)           28 (71.8)          
   \>25                          498 (17.7)             11 (28.2)          
  Concomitant diseases                                                     0.700
   No                            2,174 (77.3)           29 (74.4)          
   Yes                           639 (22.7)             10 (25.6)          
  Diabetes                                                                 0.010[\*](#tfn3-tcrm-14-965){ref-type="table-fn"}
   No                            2,680 (95.3)           33 (84.7)          
   Yes                           133 (4.7)              6 (15.3)           
  Preoperative hypoproteinemia                                             0.035[\*](#tfn3-tcrm-14-965){ref-type="table-fn"}
   No                            2,500 (88.9)           30 (76.9)          
   Yes                           313 (11.1)             9 (23.1)           
  Preoperative anemia                                                      0.424
   No                            1,256 (44.6)           20 (51.3)          
   Yes                           1,557 (55.4)           19 (48.7)          
  Tumor size (cm)                                                          0.480
   ≤5.0                          1,986 (70.6)           30 (76.9)          
   \>5.0                         827 (29.4)             9 (23.1)           
  Type of reconstruction                                                   0.146
   Roux-en-Y                     979 (34.8)             19 (48.7)          
   Billroth-I                    552 (19.6)             3 (7.7)            
   Billroth-II                   991 (35.2)             12 (30.8)          
   Esophagogastrostomy           291 (10.4)             5 (12.8)           
  Type of surgical resection                                               0.120
   Total                         979 (34.8)             19 (48.7)          
   Distal                        1,543 (54.8)           15 (38.5)          
   Proximate                     291 (10.4)             5 (12.8)           
  Surgical approach                                                        0.236
   Open                          2,234 (79.4)           28 (71.8)          
   Laparoscopic                  579 (20.6)             11 (28.2)          
  Combined organ resection                                                 0.648
   No                            2,714 (96.5)           37 (94.9)          
   Yes                           99 (3.5)               2 (5.1)            
  Neoadjuvant chemotherapy                                                 0.262
   No                            1,270 (45.1)           14 (35.9)          
   Yes                           1,543 (54.9)           25 (64.1)          
  AJCC stage                                                               0.130
   I                             210 (7.5)              4 (10.3)           
   II                            762 (27.1)             5 (12.8)           
   III                           1,841 (65.4)           30 (76.9)          

**Notes:**

*P* \< 0.05. Fisher's exact test was used to calculate the *P*-value.

**Abbreviations:** URO, unplanned reoperation; BMI, body mass index; AJCC, American Joint Committee on Cancer.

###### 

Multivariate logistic regression analysis of risk factors for URO

  Variables                      Multivariate logistic regression analysis                   
  ------------------------------ ------------------------------------------- --------------- ---------------------------------------------------
  Gender                         4.630                                       1.412--15.152   0.011[\*](#tfn5-tcrm-14-965){ref-type="table-fn"}
  Age                            1.367                                       0.452--4.136    0.579
  BMI                            1.409                                       0.485--4.095    0.529
  Concomitant diseases           1.540                                       0.480--4.941    0.467
  Diabetes                       4.189                                       1.705--10.290   0.002[\*](#tfn5-tcrm-14-965){ref-type="table-fn"}
  Preoperative hypoproteinemia   2.305                                       1.079--4.923    0.031[\*](#tfn5-tcrm-14-965){ref-type="table-fn"}
  Preoperative anemia            0.798                                       0.334--1.903    0.611
  Tumor size                     1.357                                       0.423--4.355    0.608
  Type of reconstruction         1.046                                       0.230--4.765    0.954
  Type of surgical resection     0.465                                       0.180--1.201    0.114
  Surgical approach              0.935                                       0.345--2.533    0.896
  Combined organ resection       0.856                                       0.233--3.143    0.814
  Neoadjuvant chemotherapy       1.387                                       0.153--12.566   0.771
  Postoperative AJCC stage       1.461                                       0.356--6.002    0.599

**Note:** *P* \< 0.05.

**Abbreviations:** URO, unplanned reoperation; BMI, body mass index; AJCC, American Joint Committee on Cancer.

###### 

Early surgical outcomes for patients with or without URO

  Parameters                    Non-URO group (n = 2,813)                                URO group (n = 39)                                      *P*-value
  ----------------------------- -------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------
  Hospital stay (days)          15.52 ± 6.16                                             35.03 ± 14.85                                           \<0.001[\*](#tfn7-tcrm-14-965){ref-type="table-fn"}
  Postoperative complications   423 (15.0%)[a](#tfn8-tcrm-14-965){ref-type="table-fn"}   19 (48.7%)[b](#tfn9-tcrm-14-965){ref-type="table-fn"}   \<0.001[\*](#tfn7-tcrm-14-965){ref-type="table-fn"}
  Mortality rate                6 (0.2%)[a](#tfn8-tcrm-14-965){ref-type="table-fn"}      5 (12.8%)[b](#tfn9-tcrm-14-965){ref-type="table-fn"}    \<0.001[\*](#tfn7-tcrm-14-965){ref-type="table-fn"}

**Notes:** *P* \< 0.05.

Parameters in the non-URO group refer to data after the initial operation.

Parameters in the URO group refer to data after the second operation.

**Abbreviation:** URO, unplanned reoperation.

###### 

Prognostic factors for cancer-specific survival after curative gastric cancer resection in univariate and multivariable analyses

  Prognostic factors             Cancer-specific survival                                                                                      
  ------------------------------ -------------------------- ------------------------------------------------------ ----------- --------------- ----------------------------------------------------
  URO                                                                                                                                          
   No                            1.193                      0.275                                                  1.683       0.923--3.071    0.090
   Yes                                                                                                                                         
  Gender                                                                                                                                       
   Female                        0.200                      0.655                                                  0.853       0.460--1.852    0.615
   Male                                                                                                                                        
  Age (years)                                                                                                                                  
   \<60                          0.822                      0.365                                                  1.049       0.585--1.882    0.873
   ≥60                                                                                                                                         
  BMI                                                                                                                                          
   ≤25                           1.032                      0.310                                                  1.187       0.681--2.067    0.546
   \>25                                                                                                                                        
  Concomitant diseases                                                                                                                         
   No                            0.147                      0.701                                                  0.979       0.523--1.833    0.947
   Yes                                                                                                                                         
  Diabetes                                                                                                                                     
   No                            0.656                      0.418                                                  0.718       0.272--1.892    0.502
   Yes                                                                                                                                         
  Preoperative hypoproteinemia                                                                                                                 
   No                            4.757                      0.029[\*](#tfn11-tcrm-14-965){ref-type="table-fn"}     1.831       1.126--2.978    0.015[\*](#tfn11-tcrm-14-965){ref-type="table-fn"}
   Yes                                                                                                                                         
  Anemia                                                                                                                                       
   No                            3.650                      0.056                                                  1.415       0.878--2.281    0.153
   Yes                                                                                                                                         
  Tumor size (cm)                                                                                                                              
   \<5                           0.016                      0.900                                                  0.978       0.533--1.793    0.942
   ≥5                                                                                                                                          
  AJCC stage                                                                                                                                   
   I                             17.920                     \<0.001[\*](#tfn11-tcrm-14-965){ref-type="table-fn"}   Reference                   
   II                                                                                                              2.575       0.631--10.510   0.187
   III                                                                                                             7.004       2.130--23.034   0.001[\*](#tfn11-tcrm-14-965){ref-type="table-fn"}
  Surgical approach                                                                                                                            
   Open                          2.522                      0.118                                                  0.893       0.549--1.454    0.649
   Laparoscopic                                                                                                                                
  Type of reconstruction                                                                                                                       
   Billroth-I                    0.023                      0.878                                                  0.716       0.420--1.219    0.219
   Billroth-II                                                                                                                                 
   Roux-en-Y                                                                                                                                   
   Esophagogastrostomy                                                                                                                         
  Combined organ resection                                                                                                                     
   No                            1.481                      0.224                                                  0.311       0.038--2.526    0.274
   Yes                                                                                                                                         

**Note:**

*P* \< 0.05.

**Abbreviations:** URO, unplanned reoperation; BMI, body mass index; AJCC, American Joint Committee on Cancer.
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